ClinicalTrials.gg
RecruitingNCT06694727DANUTRIO-HFUpdated Oct 3, 2025

A Danish Pragmatic Randomized Trial of Nutritional Supplements in Heart Failure

A Phase 3 interventional study of Coenzyme Q10 100 Milligrams Oral Capsule and Selenium 100 Micrograms Oral Tablets in Heart Failure, sponsored by Tor Biering-Sørensen. Recruiting at 1 site in Denmark. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2025-10-03.

Sponsored by Tor Biering-Sørensen · Phase 3, Interventional, and Treatment

How we know

From the registry’s dates

  • Started Sep 2025; still recruiting 1 year 1 month later.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 3
Study type
Interventional
Enrollment
4,044
Allocation
Randomized
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 242 studies in Heart Failure with a site in Denmark — 52 open to participants now, 60 under way, 9 of them phase 3. Heart Failure · Denmark.

Planned enrollment
24th of 187
4,044 · median 197
Started
2025
with 9 others
Phase 3
38 of 242
7 open now
Primary completion
2028-12
later than 38 of 59 live
Registered
221st of 242
by date

Among the 242 studies in Heart Failure with a site in Denmark, this one is the 24th largest by planned enrollment of the 187 interventional ones that give a count, is one of 10 that started in 2025, is one of 38 in phase 3, reaches primary completion later than 38 of the 59 other live ones, and was the 221st registered.

Heart Failure

6,340 studies on the registry are indexed under Heart Failure; 1,397 are open to participants now.

Browse Heart Failure studies →

Open to participants now

52 of the 242 studies in Heart Failure with a site in Denmark are open now. Recruiting first, the newest first:

46 more — sign in →

All 52 open studies →

A study can be open while its sites in Denmark have not opened yet or have stopped. Only those recruiting at a site in Denmark →

Who these studies take

Of the 968 Heart Failure studies recruiting now, 691 (71%) set no upper age limit and 90 (9%) stop at 75 or younger; 64 take children under 18; 97 take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 242 studies in Heart Failure with a site in Denmark, or all of them as a file.
02

Study summary

Heart failure is a common and serious condition. Despite rapid advancements in heart failure treatment, the prognosis remains severe. Smaller studies have shown that two simple, safe, and relatively inexpensive nutritional supplements-coenzyme Q10 and selenium-may reduce the risk of complications associated with heart failure. The DANUTRIO-HF trial will investigate whether these supplements can make a difference for individuals with heart failure. The study will assign approximately 4,044 patients from across Denmark to either coenzyme Q10 (100 mg twice daily) or a corresponding placebo, as well as selenium (100 μg twice daily) or its corresponding placebo, and follow how many of them end up being hospitalized for heart failure or dying from heart problems over an estimated two to three-year period.

Read the detailed description

This investigator-initiated, pragmatic, registry-based, double-blinded, placebo-controlled, 2x2 factorial, individually randomized trial aims to evaluate the efficacy of daily intake of the nutritional supplements coenzyme Q10 versus placebo, and selenium versus placebo, in preventing heart failure hospitalizations and cardiovascular death in heart failure patients. The trial plans to randomize approximately 4,044 participants in an event-driven design. Participants will be identified through the Danish Administrative Health Registries, which will also serve as the primary source for data collection. Contact with potential participants will be made via the mandatory Danish electronic letter system. No scheduled in-person visits are required in the main study, and all study interventions will be mailed to participants.

A substudy involving up to 600 participants will assess the effects of coenzyme Q10 and selenium on functional capacity, treatment compliance, biochemical biomarkers, and cardiac function and structure. This group will attend two in-person visits for additional evaluations, including echocardiography, blood sampling, and a 6-minute walk test at baseline and at the 1-year follow-up.

03

Conditions studied

  • Heart Failure

Browse trials for

Keywords

  • Heart failure
  • Coenzyme Q10
  • Selenium
  • Randomized Controlled Trial
  • Registry
  • Echocardiography
  • Pragmatic
  • Factorial
  • 2x2
  • Cardiovascular
  • Nutritional supplements
04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Individuals aged ≥ 18 years.
  • Registered with a heart failure diagnosis (ICD-10: I50) as a primary discharge diagnosis in The Danish National Patient Registry and at least one claimed prescription of a renin-angiotensin-system inhibitor and a β-blocker within 120 days after HF diagnosis.
  • form has been signed and dated.

Exclusion criteria

Exclusion Criteria:

  • Use of vitamin K-antagonist
  • Registered with a cancer diagnosis (C00-C97 not C44) within the last 5 years excluding cutaneous squamous cell or basal cell carcinoma in The Danish National Patient Registry.
Terms in these criteria, in plain language(1)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

05

Study design

Phase
Phase 3
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Factorial assignment
Masking
Quadruple (Participant, Care provider, Investigator, Outcomes assessor)
Enrollment
4,044 participants (estimated)

Study arms

  • Experimental
    Coenzyme Q10 intervention, active

    100 mg capsules given twice daily, per oral use

    Dietary Supplement: Coenzyme Q10 100 Milligrams Oral Capsule

  • Placebo comparator
    Coenzyme Q10 intervention, placebo

    Placebo matching coenzyme Q10

    Dietary Supplement: Coenzyme Q10 100 Milligrams Oral Capsule

  • Experimental
    Selenium intervention, active

    100 μg tables given twice daily, per oral use

    Dietary Supplement: Selenium 100 Micrograms Oral Tablets

  • Placebo comparator
    Selenium intervention, placebo

    100 μg tables given twice daily, per oral use

    Dietary Supplement: Selenium 100 Micrograms Oral Tablets

Interventions

  • Dietary supplementCoenzyme Q10 100 Milligrams Oral Capsule

    100 mg capsules given twice daily, per oral use.

  • Dietary supplementSelenium 100 Micrograms Oral Tablets

    100 μg tablets given twice daily, per oral use.

06

What researchers measure

Primary outcomes

  1. Time to the first occurrence of hospitalization for heart failure or cardiovascular death

    Time frame: From date of randomization until end of study (Up to approximately 33 months)

Secondary outcomes

  1. Time to first occurrence of hospitalization for heart failure

    Time frame: From date of randomization until end of study (Up to approximately 33 months)

  2. Time to cardiovascular death

    Time frame: From date of randomization until end of study (Up to approximately 33 months)

Other outcomes

  1. Total number of hospitalizations for heart failure

    Time frame: From date of randomization until end of study (Up to approximately 33 months)

  2. Total number of hospitalizations for heart failure and cardiovascular death

    Time frame: From date of randomization until end of study (Up to approximately 33 months)

  3. Time to the first occurrence of hospitalization for heart failure or all-cause death

    Time frame: From date of randomization until end of study (Up to approximately 33 months)

  4. Total number of hospitalizations for heart failure and all-cause death

    Time frame: From date of randomization until end of study (Up to approximately 33 months)

  5. Time to all-cause mortality

    Time frame: From date of randomization until end of study (Up to approximately 33 months)

  6. Time to first occurrence of major adverse cardiovascular events

    Time frame: From date of randomization until end of study (Up to approximately 33 months)

  7. Total number of major adverse cardiovascular events

    Time frame: From date of randomization until end of study (Up to approximately 33 months)

  8. Time to first occurrence of hospitalization for any cardiovascular disease

    Time frame: From date of randomization until end of study (Up to approximately 33 months)

  9. Total number of hospitalizations for any cardiovascular disease

    Time frame: From date of randomization until end of study (Up to approximately 33 months)

  10. Time to first occurrence of hospitalization for any cardiorespiratory disease

    Time frame: From date of randomization until end of study (Up to approximately 33 months)

  11. Total number of hospitalizations for any cardiorespiratory disease

    Time frame: From date of randomization until end of study (Up to approximately 33 months)

  12. Time to first hospitalization for atrial fibrillation

    Time frame: From date of randomization until end of study (Up to approximately 33 months)

  13. Total number of hospitalizations for atrial fibrillation

    Time frame: From date of randomization until end of study (Up to approximately 33 months)

  14. Time to first occurrence of hospitalization for cardiac arrest

    Time frame: From date of randomization until end of study (Up to approximately 33 months)

  15. Time to first hospitalization for any cause

    Time frame: From date of randomization until end of study (Up to approximately 33 months)

  16. Total number of hospitalizations for any cause

    Time frame: From date of randomization until end of study (Up to approximately 33 months)

  17. Change in Kansas City Cardiomyopathy Questionnaire Score

    Time frame: Aproximately within 1 year after randomization

  18. Change in left ventricular ejection fraction assessed with echocardiography

    In up to 600 participants in a planned substudy with two physical visits. One shortly after randomization and another 1 year after

    Time frame: Aproximately within 1 year after randomization

  19. Change in left ventricular global longitudinal strain assessed with echocardiography

    In up to 600 participants in a planned substudy with two physical visits. One shortly after randomization and another 1 year after

    Time frame: Aproximately within 1 year after randomization

  20. Change in E/e'-ratio assessed with echocardiography

    In up to 600 participants in a planned substudy with two physical visits. One shortly after randomization and another 1 year after

    Time frame: Aproximately within 1 year after randomization

  21. Change in left ventricular mass assessed with echocardiography

    In up to 600 participants in a planned substudy with two physical visits. One shortly after randomization and another 1 year after

    Time frame: Aproximately within 1 year after randomization

  22. Change in interventricular septal wall thickness assessed with echocardiography

    In up to 600 participants in a planned substudy with two physical visits. One shortly after randomization and another 1 year after

    Time frame: Aproximately within 1 year after randomization

  23. Change in left ventricular posterior thickness assessed with echocardiography

    In up to 600 participants in a planned substudy with two physical visits. One shortly after randomization and another 1 year after

    Time frame: Aproximately within 1 year after randomization

  24. Change in left atrial volume assessed with echocardiography

    In up to 600 participants in a planned substudy with two physical visits. One shortly after randomization and another 1 year after

    Time frame: Aproximately within 1 year after randomization

  25. Change in left atrial resevoir strain assessed with echocardiography

    In up to 600 participants in a planned substudy with two physical visits. One shortly after randomization and another 1 year after

    Time frame: Aproximately within 1 year after randomization

  26. Change in left atrial contraction strain assessed with echocardiography

    In up to 600 participants in a planned substudy with two physical visits. One shortly after randomization and another 1 year after

    Time frame: Aproximately within 1 year after randomization

  27. Change in left atrial conduit strain assessed with echocardiography

    In up to 600 participants in a planned substudy with two physical visits. One shortly after randomization and another 1 year after

    Time frame: Aproximately within 1 year after randomization

  28. Change in tricuspid annular plane systolic excursion assessed with echocardiography

    In up to 600 participants in a planned substudy with two physical visits. One shortly after randomization and another 1 year after

    Time frame: Aproximately within 1 year after randomization

  29. Change in right ventricular free wall longitudinal strain assessed with echocardiography

    In up to 600 participants in a planned substudy with two physical visits. One shortly after randomization and another 1 year after

    Time frame: Aproximately within 1 year after randomization

  30. Change in pro-BNP

    In up to 600 participants in a planned substudy with two physical visits. One shortly after randomization and another 1 year after

    Time frame: Aproximately within 1 year after randomization

  31. Change in high sensitivity troponin-I

    In up to 600 participants in a planned substudy with two physical visits. One shortly after randomization and another 1 year after

    Time frame: Aproximately within 1 year after randomization

  32. Change in hs-CRP

    In up to 600 participants in a planned substudy with two physical visits. One shortly after randomization and another 1 year after

    Time frame: Aproximately within 1 year after randomization

  33. Concentration of coenzyme Q10 at followup

    In up to 600 participants in a planned substudy with two physical visits. One shortly after randomization and another 1 year after

    Time frame: Aproximately within 1 year after randomization

  34. Concentration of selenoprotein P and selenium at followup

    In up to 600 participants in a planned substudy with two physical visits. One shortly after randomization and another 1 year after

    Time frame: Aproximately within 1 year after randomization

  35. Change in 6 minute walking distance

    In up to 600 participants in a planned substudy with two physical visits. One shortly after randomization and another 1 year after

    Time frame: Aproximately within 1 year after randomization

07

Study locations

1 of 1 sites recruiting
08

References and documents

Individual participant data

Plan to share: Yes — Most data will be collected from Danish administrative health registries, which are subject to Danish legislation and can only be made available to a third party under certain conditions. Please contact the sponsor-investigator in case of any inquiries.

Supporting information: Study protocol, Statistical analysis plan

No publications or documents are linked to this record.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started Sep 2025 (actual). Primary completion is estimated for Dec 2028, 38 months after the start.

Of 87 non-industry phase 3 interventional studies under Heart Failure, half reached primary completion within 50 months of starting (the median), counting those still running; a quarter within 28 and three quarters within 63. This study's planned 38 months is below that.

Counting every sponsor, half of 150 studies reached it within 39 months; a quarter within 26 and three quarters within 57.

How these figures are worked out, and which studies are left out of them.

Registered
Oct 28, 2024
First posted
Nov 19, 2024
StartActual
Sep 30, 2025
Primary completionEst.
Dec 1, 2028
CompletionEst.
Jun 1, 2029
Last update
Oct 3, 2025
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Oct 3, 2025, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT06694727
Lead sponsor
Tor Biering-Sørensen
Collaborators
Pharma Nord
Responsible party
Tor Biering-Sørensen (Professor, MD, MSc, MPH, PhD, Herlev and Gentofte Hospital) — Sponsor-investigator
First posted
Nov 19, 2024
Start date
Sep 30, 2025
Primary completion
Dec 1, 2028 (estimated)
Completion
Jun 1, 2029 (estimated)
Last update
Oct 3, 2025

Study contacts

Kristoffer G Skaarup, MD
Contact
kristoffer.grundtvig.skaarup@regionh.dk
+4542451250
Tor Biering-Sørensen, MD, MPH, MSc, PhD
Contact
tor.biering-soerensen@regionh.dk
+4528933590
Tor Biering-Sørensen, MD, MPH, MSc, PhD
principal investigator · Center for Translational Cardiology and Pragmatic Randomized Trials, Department of Cardiology, Copenhagen University Hospital - Herlev and Gentofte

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion